Name

上海药明康德新药开发有限公司

Legal name

无锡药明康德新药开发股份有限公司

Website

https://wuxiapptec.com.cn

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research, Development and Manufacturing (CRDMO) Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract research services
• Pharmaceutical development
• Drug manufacturing
• Clinical testing services
• Oligonucleotide synthesis

Headquarters

HQ city

浦东, 上海

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. WuXi Chemistry (Chemical Business): Provides end-to-end services from chemical drug discovery to commercial manufacturing. Includes small molecule drug discovery (R), process development and manufacturing (D&M), and TIDES (oligonucleotide and peptide) services. 2025 revenue of 364.7 billion RMB with 25.5% YoY growth. Small molecule D&M revenue of 199.2 billion RMB in 2025. TIDES revenue of 113.7 billion RMB with 96% YoY growth.
2. WuXi Testing: Comprehensive testing services including drug safety evaluation, DMPK and pre-clinical services. 2025 revenue of 40.4 billion RMB with 4.7% YoY growth. Drug safety evaluation business maintained Asia-Pacific industry leadership.
3. WuXi Biology: Biology research and drug discovery services including in-vitro and in-vivo capabilities. 2025 revenue of 26.8 billion RMB with 5.2% YoY growth.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

WuXi AppTec operates an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform delivering end-to-end pharmaceutical services from drug discovery through commercial manufacturing. Its three core service platforms—WuXi Chemistry (small molecule and TIDES oligonucleotide/peptide discovery, development and manufacturing), WuXi Biology (target discovery, in-vitro/in-vivo pharmacology and candidate screening) and WuXi Testing (drug safety evaluation, DMPK and pre-clinical testing)—serve global pharmaceutical and biotechnology clients across more than 30 countries.

Product overview

WuXi AppTec (药明康德) operates an integrated CRDMO (Contract Research, Development and Manufacturing Organization) business model offering end-to-end pharmaceutical development services. The company provides three core platforms: WuXi Chemistry (chemical drug discovery and manufacturing including TIDES oligonucleotides and peptides), WuXi Biology (comprehensive biology services for drug discovery), and WuXi Testing (drug development testing solutions including safety evaluation and DMPK). The integrated CRDMO platform enables customers to advance molecules from research through development and commercial manufacturing, with operations spanning Asia, Europe and North America.

Differentiator

Problem solved

Functional benefit

Brands

• WuXi Chemistry: Chemical drug discovery, research, and commercial manufacturing services under CRDMO model
• WuXi Biology
• WuXi Testing
• TIDES
• WuXi STA (合全药业)

Products and services

• WuXi Chemistry (化学业务平台) Chemical business platform providing end-to-end CRDMO services from chemical drug discovery research to commercial manufacturing for global pharmaceutical clients, including small molecule and TIDES (oligonucleotides and peptides) services.
• WuXi Biology (生物学业务平台) Comprehensive biology services and solutions supporting target discovery through candidate drug screening and clinical development, including in vitro and in vivo pharmacology capabilities for pharmaceutical and biotechnology clients.
• WuXi Testing (测试业务平台) Testing business platform providing full lifecycle integrated drug development testing solutions, including drug safety evaluation and DMPK services, maintaining global high-quality standards for pharmaceutical clients.
• TIDES (Oligonucleotides and Peptides) Oligonucleotides and peptides development and manufacturing services for emerging therapeutic modalities under WuXi Chemistry, with multi-pillar synthesis reactor capacity exceeding 100,000L and 2025 TIDES business revenue of 113.7 billion RMB (96% YoY growth).
• WuXi STA (合全药业) Small molecule R&D and manufacturing subsidiary providing pharmaceutical drug substance and drug product manufacturing services, including API manufacturing operations across U.S. sites in Middletown, Delaware and San Diego, California.
• WuXi DMPK Drug metabolism and pharmacokinetics (DMPK) and pre-clinical services operated from the Cranbury, New Jersey facility, supporting pharmaceutical and biotech clients with pre-clinical pharmacology testing.
• LabNetwork (览博网) Compound Library Service Platform Compound library service platform providing researchers with compound library design, search, ordering and screening services, offering access to WuXi AppTec's novel screening compound libraries and one-stop biology screening services for drug discovery researchers.

Quantifiable outcome

• 2025 revenue of 454.6 billion RMB with 15.8% growth; continuing operations 21.4% YoY
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered strategic and core.

• NEOM (Saudi Arabia)strategicStrategic or Co-development Partner · 28 October 2025WuXi AppTec signed strategic cooperation memorandums with NEOM (New Future City project in Saudi Arabia) and Saudi Ministry of Health to expand CRDMO platform services locally. NEOM is a sustainable development city under construction in northwestern Saudi Arabia.
• Saudi Ministry of HealthstrategicStrategic or Co-development Partner · 28 October 2025Strategic cooperation memorandum signed with Saudi Ministry of Health to explore expanding CRDMO platform services in Saudi Arabia, supporting the country's healthcare and pharmaceutical development objectives.
• United Nations Global Compact (UNGC)coreOthersWuXi AppTec has joined the UN Global Compact, committing to support the ten principles of the UNGC and integrating sustainable business practices into company operations.
• Pharmaceutical Supply Chain Initiative (PSCI)coreOthersAs a PSCI supplier partner, WuXi AppTec participates in the pharmaceutical supply chain initiative promoting responsible supply chain practices in the pharmaceutical industry.
• Science Based Targets initiative (SBTi)coreOthersWuXi AppTec's near-term greenhouse gas emission reduction targets have been validated and approved by SBTi, demonstrating commitment to science-based climate action.

Scale indicators13 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• Samsung Biologics: Korean CDMO specializing in biologics contract manufacturing with large-scale mammalian capacity. Comparable to WuXi's biologics-adjacent CDMO scale and global pharma client base.
• Charles River Laboratories: US CRO/CDMO providing discovery, safety assessment and manufacturing services to pharma/biotech. Directly comparable to WuXi's Biology and Testing (DSE) platforms and competes for outsourced preclinical work.
• Lonza Group: Swiss-headquartered global CDMO leader offering API, biologics and integrated drug substance/product manufacturing. Closely comparable to WuXi AppTec in integrated small molecule and oligonucleotide/peptide CDMO services to global pharma.
• Catalent (Novo Holdings): Major US-headquartered CDMO providing drug substance, drug product and biologics development/manufacturing, recently taken private by Novo Holdings. Directly comparable to WuXi in commercial-stage small molecule and biologics CDMO offerings.

Regional players

• Recipharm: European CDMO offering pharmaceutical formulation, API and drug product manufacturing services, now part of the Recipharm/Dr. Reddy's ecosystem. Comparable CDMO business model to WuXi, focused on the European pharma customer base.

Broad incumbents

• IQVIA: Global CRO and clinical/research services giant serving pharma across R&D, clinical trials and real-world evidence. Broader incumbent that overlaps WuXi's clinical/biology/testing services but at much larger scale and different mix.
• ICON plc: Ireland-headquartered global CRO providing clinical research services to pharma/biotech. Comparable to the clinical research portion of WuXi's former China Clinical Research Services business (now divested).
• Thermo Fisher Scientific (Patheon CDMO): Diversified life sciences tools and CDMO operator (via Patheon) offering drug substance/product manufacturing and clinical supply services. Broad incumbent competing with WuXi for integrated small molecule and biologics CDMO work.

Emerging players

• Syneos Health: US-based clinical and commercial CRO with end-to-end pharma services. Comparable to WuXi's clinical services offering prior to the 2025 China Clinical Research Services divestiture.
• WuXi Biologics: Hong Kong-listed biologics CDMO with global manufacturing footprint, spun out of the broader WuXi ecosystem. Closely comparable in CRDMO model and biologics manufacturing, though focused on biologics rather than WuXi AppTec's broader small molecule/TIDES mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E4%B8%8A%E6%B5%B7%E8%8D%AF%E6%98%8E%E5%BA%B7%E5%BE%B7%E6%96%B0%E8%8D%AF%E5%BC%80%E5%8F%91%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 上海药明康德新药开发有限公司